Scholarlink

<p>Given the rising incidence of allergic asthma, current symptomatic treatments primarily offer relief rather than halt disease progression. A compelling argument exists for gene therapy to treat this disease, as recombinant allergens, designed with reduced immunoglobulin E (IgE) reactivity and the ability to regulate excessive T helper type 2 responses, are emerging as promising candidates for more precise, effective, and safer allergen-specific immunotherapy. Here, we report an adeno-associated virus (AAV) 6.2FF capsid that demonstrates efficiency in lung epithelial cell transduction based on imaging and flow cytometry analysis. Intratracheal administration of this vector delivering two house dust mite antigens (Der p1 and Der p2, AAV-Dp12S) into allergic asthma mice significantly attenuated the HDM-induced asthmatic phenotype and improves lung physiology. Following AAV-Dp12S treatment, correlating with marked reductions in goblet cell hyperplasia and pulmonary eosinophilia. Moreover, total serum IgE, HDM-specific IgE (sIgE) titers, and pulmonary inducible nitric oxide synthase levels were effectively reduced. The cytokine profiles in bronchoalveolar lavage fluid (BALF) were modulated, as indicated by decreased levels of type 2 cytokines-interleukin (IL)-4, IL-5, and IL-13—and increased levels of interferon-γ and IL-10. Additionally, sIgE titers and production were significantly lowered. Overall, these findings demonstrate the potential of AAV-Dp12S as a therapeutic strategy for both tolerance induction and vaccination in the treatment of allergic asthma.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The adeno associated viral vectored Dp12S vaccine effective alleviation of asthma symptoms in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Shengbin Liu,
  • Jiangzhou Chu,
  • Xiaoling Yin,
  • Anying Xiong,
  • Yaoyao Luo,
  • Jinxiu Xin,
  • Zhongshan He,
  • Shugang Qin

摘要

Given the rising incidence of allergic asthma, current symptomatic treatments primarily offer relief rather than halt disease progression. A compelling argument exists for gene therapy to treat this disease, as recombinant allergens, designed with reduced immunoglobulin E (IgE) reactivity and the ability to regulate excessive T helper type 2 responses, are emerging as promising candidates for more precise, effective, and safer allergen-specific immunotherapy. Here, we report an adeno-associated virus (AAV) 6.2FF capsid that demonstrates efficiency in lung epithelial cell transduction based on imaging and flow cytometry analysis. Intratracheal administration of this vector delivering two house dust mite antigens (Der p1 and Der p2, AAV-Dp12S) into allergic asthma mice significantly attenuated the HDM-induced asthmatic phenotype and improves lung physiology. Following AAV-Dp12S treatment, correlating with marked reductions in goblet cell hyperplasia and pulmonary eosinophilia. Moreover, total serum IgE, HDM-specific IgE (sIgE) titers, and pulmonary inducible nitric oxide synthase levels were effectively reduced. The cytokine profiles in bronchoalveolar lavage fluid (BALF) were modulated, as indicated by decreased levels of type 2 cytokines-interleukin (IL)-4, IL-5, and IL-13—and increased levels of interferon-γ and IL-10. Additionally, sIgE titers and production were significantly lowered. Overall, these findings demonstrate the potential of AAV-Dp12S as a therapeutic strategy for both tolerance induction and vaccination in the treatment of allergic asthma.